Dr. Shao-An Xue
Shao-An Xue, Senior Lecturer in Tumor Immunology and Cancer Immunotherapy, University College London Medical School, U. K. / Xi’An University, P. R. China.Dr Shao-An Xue has been in the field of viral oncology and cancer immunotherapy for 20 years, and has successfully developed a new strategy for cancer immunotherapy based on T cell receptor (TCR) gene transfer. He has been able to demonstrate that T cells transduced with a TCR specific for the Wilm’s tumor antigen (WT1-TCR) can recognize their specific targets and selectively kill leukemia progenitor cells, without damage to normal CD34+ these TCR-engineered patient’s T cells can eliminate leukemia progenitor cells in situations where control T cells prove ineffective. He received George Brecher New Investigator Award from the International Society for Experimental Hematology (ISEH) in 2005 (http://www.iseh.org/?page=PastNIRecipients) acknowledging this, and this work has progressed to a phase I/II clinical trial now (http://clinicaltrials.gov/show/NCT01621724). Apart from developing the leukemia specific WT1-TCR, Dr Xue has also developed many other tumor specific TCRs, including EBV-TCR, CMV-TCR and HBV-TCR, and all of these TCRs are in the first in man clinical trials now. Due to his contribution and influence in the field of TCR immunogene therapy of cancer, he has been invited as editorial board member on several international journals, including Journal of Immunotherapy applications, Annals of Vaccines and Immunization, World Journal of Hematology, Journal of Hematological Malignancies and Journal of Molecular Cytotherapy. He has also served as an Expert panel member on the clinical microbiology and immunology panel of the European Society for Translational Medicine. Dr Xue received his PhD degree in Viral Oncology from Imperial College London, United Kingdom, in 1999.